<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ling X</submitter><funding>Beijing Medical Award Foundation</funding><funding>Haiyan Foundation of Harbin Medical University Cancer Hospital</funding><funding>National Natural Science Foundation of China</funding><pagination>310</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11385129</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Phosphofructokinase P (PFKP) is a key rate-limiting enzyme in glycolysis, playing a crucial role in various pathophysiological processes. However, its specific function in tumors remains unclear. This study aims to evaluate the expression and specific role of PFKP across multiple tumor types (Pan-cancer) and to explore its potential clinical significance as a therapeutic target in cancer treatment.&lt;h4>Methods&lt;/h4>We analyzed the expression of PFKP, immune cell infiltration, and patient prognosis across various cancers using data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Additionally, we conducted a series of experiments in lung cancer cells, including Western blot, CCK-8 assay, colony formation assay, transwell migration assay, scra</pubmed_abstract><journal>Cancer cell international</journal><pubmed_title>A comprehensive prognostic and immunological implications of PFKP in pan-cancer.</pubmed_title><pmcid>PMC11385129</pmcid><funding_grant_id>82172786</funding_grant_id><funding_grant_id>JJMS2023-04</funding_grant_id><funding_grant_id>No. YXJL-2023-0091-0054</funding_grant_id><pubmed_authors>Ling X</pubmed_authors><pubmed_authors>Liang H</pubmed_authors><pubmed_authors>Fang C</pubmed_authors><pubmed_authors>Ma J</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>A comprehensive prognostic and immunological implications of PFKP in pan-cancer.</name><description>&lt;h4>Background&lt;/h4>Phosphofructokinase P (PFKP) is a key rate-limiting enzyme in glycolysis, playing a crucial role in various pathophysiological processes. However, its specific function in tumors remains unclear. This study aims to evaluate the expression and specific role of PFKP across multiple tumor types (Pan-cancer) and to explore its potential clinical significance as a therapeutic target in cancer treatment.&lt;h4>Methods&lt;/h4>We analyzed the expression of PFKP, immune cell infiltration, and patient prognosis across various cancers using data from the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases. Additionally, we conducted a series of experiments in lung cancer cells, including Western blot, CCK-8 assay, colony formation assay, transwell migration assay, scra</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Sep</publication><modification>2025-04-04T12:10:17.007Z</modification><creation>2025-04-04T12:10:17.007Z</creation></dates><accession>S-EPMC11385129</accession><cross_references><pubmed>39252014</pubmed><doi>10.1186/s12935-024-03497-w</doi></cross_references></HashMap>